Chelation Therapy in Coronary Artery Disease: Fact or Fiction?

Area of Science:

• Cardiovascular Medicine
• Toxicology
• Alternative Therapies

Background:

• Coronary artery disease (CAD) is a major global cause of death, driven by arterial plaque buildup.
• Chelation therapy, utilizing ethylenediaminetetraacetic acid (EDTA), has been investigated as a potential treatment for atherosclerotic CAD.
• Previous research, like the 2013 Trial to Assess Chelation Therapy (TACT), suggested modest cardiovascular benefits, particularly in diabetic patients.

Purpose of the Study:

• To evaluate the efficacy of chelation therapy in treating patients with coronary artery disease.
• To determine if chelation therapy reduces cardiovascular events, especially in patients with diabetes.
• To assess the safety and adverse effects associated with chelation therapy in CAD patients.

Main Methods:

• The study references the Trial to Assess Chelation Therapy (TACT) and subsequent TACT2 trial.
• Participants received chelation therapy involving ethylenediaminetetraacetic acid.
• Cardiovascular events and adverse effects were monitored in study participants.

Main Results:

• The initial TACT trial indicated modest cardiovascular benefits, notably in patients with diabetes.
• Subsequent studies, including TACT2, failed to replicate these findings and did not confirm efficacy in reducing cardiovascular events in diabetic patients.
• No significant adverse effects, such as renal dysfunction or fatal complications, were observed in the TACT or TACT2 trials.

Conclusions:

• Chelation therapy's effectiveness in reducing cardiovascular events in patients with coronary artery disease, particularly those with diabetes, remains unproven by subsequent trials.
• While serious adverse events were not observed in the TACT and TACT2 trials, the lack of confirmed efficacy limits its therapeutic recommendation.
• Further research may be needed to clarify the role, if any, of chelation therapy in managing atherosclerotic CAD.